BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
The largest sun of 2026 rises today as Earth draws closest to our parent star - 2Sources: IDF does not actually know how many ballistic missiles Iran has left
- 3The Best Computer games for Multiplayer Fun
- 4Guns N' Roses 2026 Tour: How to get tickets, presale times, prices and more
- 5The Strait of Hormuz Isn’t Just an Oil Problem, It’s Now a Food Problem
- The Best Portable Applications for Psychological wellness and Prosperity
- 6 Famous kind of practice on the planet
- Foot fossil discovery could reshape human evolutionary history
- This Week In Space podcast: Episode 187 — An Inspired Enterprise
- Merz: 80% of Syrians in Germany expected to return within three years
- Going on a bad date is a drag. Worse? Ending up as a cautionary tale on TikTok.
- NASA releases new ‘Earthset’ and eclipse images taken during historic flyby of the moon
- Far-right leader Le Pen to attend Brigitte Bardot's funeral
- Most loved Amusement Park Firecrackers Show: Which One Lights Up Your Evening?
